Answers are grounded in this paper and cite their sources.
The potassium salts of H2NC(S)NHP(S)(OiPr)2 (HLI) or o‐C6H4[NHC(S)NHP(S)(OiPr)2]2 (H2LII) react with [Cu(PPh3)3I] or a mixture of CuI and Ph2P(CH2)1–3PPh2 or Ph2P(C5H4FeC5H4)PPh2 in aqueous EtOH/CH2Cl2 to give mononuclear complexes [Cu(PPh3)LI] (1), [Cu{Ph2P(CH2)2PPh2}LI] (2), [Cu{Ph2P(CH2)3PPh2}LI] (3) or [Cu{Ph2P(C5H4FeC5H4)PPh2}LI] (4), or dinuclear complexes [Cu2(Ph2PCH2PPh2)LI2] (5), [Cu2(PPh3)2LII] (6), [Cu2{Ph2P(CH2)2PPh2}2LII] (7), [Cu2{Ph2P(CH2)3PPh2}2LII] (8), [Cu2{Ph2P(C5H4FeC5H4)PPh2}2LII] (9) or [Cu2(Ph2PCH2PPh2)LII] (10). The structures of these compounds were investigated by 1H and 31P{1H} NMR, UV/Vis spectroscopy and elemental analysis. The crystal structures of H2LII, 1, 3–6, 8 and 10 were determined by single‐crystal X‐ray diffraction. The luminescent properties of complexes 1–10 in the solid state are reported.
No takes yet. Share an insight, caveat, or question.
Babashkina et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: